| 张丽婷,刘贤忠,宋康,陈芳.肺积汤对Lewis肺癌裸鼠移植瘤中新生血管的影响[J].浙江中西医结合杂志,2019,29(10): |
| 肺积汤对Lewis肺癌裸鼠移植瘤中新生血管的影响 |
|
| 投稿时间：2019-03-26 修订日期：2019-08-26 |
| DOI： |
| 中文关键词: 肺癌，血管新生，血管内皮生长因子，微血管密度，肺积汤，贝伐单抗 |
| 英文关键词: |
| 基金项目:保肺定喘汤对慢性阻塞性肺病中VEGF信号通路的影响,国家自然科学基金项目（面上项目，重点项目，重大项目） |
|
| 摘要点击次数: 807 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的 观察肺积汤对Lewis肺癌移植瘤中新生血管的影响，并探讨其机制，为中医中药在抑制肺癌生长及转移的临床应用提供实验基础和理论依据。方法 BALB/c雄性裸鼠30只，制作Lewis肺癌模型，随机数字表法随机分为3组，对照组（NS组：0.9%NS 0.4ml/只，灌胃，qd）；中药组（生药含量1g/ml： 22.2mg/kg，调整至0.4ml/只，灌胃，qd）；贝伐单抗组（贝伐单抗15mg/kg，调整至0.2ml/只，腹腔注射，biw），给药21天后处死，收集血清、皮下瘤。HE染色观察皮下瘤血管情况，免疫组化法检测皮下瘤微血管密度（MVD）、血管内皮生长因子-A（VEGF-A）的水平；ELISA法测定血清中VEGF-A水平。结果（1）一般情况：相对于对照组，中药组及贝伐单抗组瘤重小[(6.15±1.49)g，(4.32±0.77)g比（7.92±1.09）g，P均<0.05]，瘤体积小[(3.73±1.06) cm3，(2.36±1.99）cm3比(6.15±1.49) cm3, P均<0.05]；且中药组裸鼠较贝伐单抗组未出现明显恶病质表现。（2）HE染色：中药组及贝伐单抗组皮下瘤细胞变性坏死较少，散在红细胞少。（3）免疫组化：中药组及贝伐单抗组MVD小[(18.39±1.21), (17.40±0.8)比( 27.40±10.12) , P<0.05]；VEGF-A表达低[(3.35±1.151), (3.22±1.10)比(6.98±1.74), P<0.05]，但中药组与贝伐单抗组组间差异小，无统计学意义（P>0.05）。（4）ELISA：中药及贝伐单抗可下调血清VEGF-A表达[(115.38±9.15)，(106.21±3.15)比(130.63±4.51), P均<0.01]。结论 （1）肺积汤能抑制皮下瘤生长，延缓恶病质发生；（2）肺积汤能下调组织及血清VEGF-A的阳性表达，降低微血管密度，维持血管稳态。（3）肺积汤抑制肿瘤生长及转移，可能与下调促血管生长因子表达，抑制肿瘤血管新生有关。 |
| 英文摘要: |
| ABSTRACT: Objective By observing the effect of Feiji Decoction to the angiogenesis on the growth and metastasis of Lewis lung carcinoma,explore the mechanism.Methods Thirty male BALB/c nude mices were randomed into three groups by random number table method:control group(0.9%NS 0.4ml,ig,qd),Feiji Decoction group(Feiji Decoction 22.2mg/kg，ig，qd) and bevacizumab group(bevacizumab 15mg/kg，ip，biw) after they were transplanted Lewis lung carcinoma cell and appeared subcutaneous tumor.After 3 weeks by administration,the mices were killed,The transplated tumor were maked into pathological section to oberse the vessel, to get the expression of MVD(microvessel densit,MVD), VEGF-A(vascular endothelial growth factor A,VEGF-A) of tumor by immunohistochemistry.ElISA was performed to detect the expression of VEGF-A in serum. Results: (1)General obversion: The tumor weight(TW),tumor volume(TV) in Feiji Decoction group and bevacizumab group are lower than NS group[TW :(6.15±1.49)g，(4.32±0.77)gVS（7.92±1.09）g，P<0.05;TV:(3.73±1.06) cm3，(2.36±1.99）cm3VS (6.15±1.49) cm3, P均<0.05]and the NS group have the express of cancer cachexia while Feiji Decoction group doesn’t.(2) HE staining: The subcutaneous tumor of Feiji Decoction group and bevacizumab group have less necrosis,less abnormal vessels, less abnormal vessels,less necrosis. (3)Immunohistochemistry: The expression of MVD、VEGF-A in Feiji Decoction group and bevacizumab group are less than NS group[MVD :(18.39±1.21), (17.40±0.8) VS ( 27.40±10.12) , P<0.05；VEGF-A(3.35±1.151), (3.22±1.10) VS (6.98±1.74), P<0.05], but between bevacizumab group and Feiji Decoction group, the difference in statistical is innsignificance(P>0.05).(4)ELISA of serum: Feiji Decoction and bevacizumab can the reduc the expression of VEGF-A [(115.38±9.15)，(106.21±3.15) VS (130.63±4.51), P<0.05]。Conclusion: (1)Feiji Decoction can inhibit the growth, relax cancer cachexia.(2)Feiji Decoction can restrain the expression of VEGF-A in tissues and serum,than depress MVD, Maintaining vascular homeostasis (3)Feiji Decoction can depress development of lung carcinoma may be associated with low expression of turmor angiogenesis factors, could be involved in angiogenesis.
Subject words:lung carcinoma,angiogenesis,vascular endothelial growth factor, microvessel density,Feiji Decoction,bevacizumab |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
